On a GAAP basis, ABBV reported net income of $ 1.39 billion or 85 cents per share, compared with income of $ 1.52 billion or 92 cents per share, a year ago period.
The consensus recommendation, according to Zacks Investment research, is 2.5. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company's stock.
Sell side analysts that regularly cover the stock have provided price targets and recommendations on AbbVie Inc.
Sales of some of the company's smaller drugs were less than what analysts were predicting. This shows a surprise factor of 0.8%.
AbbVie acquired half-ownership of Imbruvica in 2015 through the buyout of Pharmacyclics Inc as part of efforts to reduce its dependence on its arthritis treatment Humira. Earnings, with 17 analysts believing the company would generate an Average Estimate of $1.19. For the quarter, the stock has changed 1.44%.
Total revenue jumped 6.2% to $6.8 billion, below the estimate of $6.91 billion by analysts surveyed by Thomson Reuters.
These analysts also forecasted Growth Estimates for the Current Quarter for ABBV to be 5.3%. The High Revenue estimate is predicted as 7.15 Billion, while the Low Revenue Estimate prediction stands at 6.75 Billion. The company's revenue was up 7.4% compared to the same quarter a year ago. The consensus estimates are $5.47 in EPS and $28.16 billion in revenue for the 2017 full year. While for the next 5 years, the growth estimate is 15.53%. AbbVie Inc was Downgraded by Credit Suisse to " Neutral" on Oct 31, 2016.
Insider Trades for AbbVie Inc. show that the latest trade was made on 8 Dec 2016 where Gosebruch (Henry O), the Officer completed a transaction type "Sell" in which 13871 shares were traded at a price of $60.9. AbbVie Inc makes up approx 0.78% of First Western Capital Management Co's portfolio.Gw&k Investment Management boosted its stake in ABBV in the latest quarter, The investment management firm added 27,365 additional shares and now holds a total of 481,811 shares of AbbVie Inc which is valued at $29,867,464.
18 analysts projected Price Targets for AbbVie Inc. The Low Price target projection by analysts is $49 and the Mean Price Target is $69.94. Its 52-week High Value is $68.12 while its 52-week Low value is $51.6. Buckingham Asset Management LLC now owns 14,579 shares of the company's stock valued at $903,000 after buying an additional 45 shares in the last quarter. The Return on Equity (ROE) and Return on Investment values are 117.5 percent and 16.9 percent respectively.
The (Simple Month Average) SMA20 is at -0.93 percent, its SMA50 Value is 0.29% and SMA200 value is reported as 0.28 Percent. The company has a market cap of $99.75 billion, a PE ratio of 16.59 and a beta of 1.58.